Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer - PubMed (original) (raw)
Clinical Trial
. 2010 Feb 1;70(3):875-82.
doi: 10.1158/0008-5472.CAN-09-2762. Epub 2010 Jan 26.
Lynn C Hartmann, William A Cliby, Harry J Long, Prema P Peethambaram, Brigitte A Barrette, Judith S Kaur, Paul J Haluska Jr, Ileana Aderca, Paula J Zollman, Jeff A Sloan, Gary Keeney, Pamela J Atherton, Karl C Podratz, Sean C Dowdy, C Robert Stanhope, Timothy O Wilson, Mark J Federspiel, Kah-Whye Peng, Stephen J Russell
Affiliations
- PMID: 20103634
- PMCID: PMC2890216
- DOI: 10.1158/0008-5472.CAN-09-2762
Clinical Trial
Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer
Evanthia Galanis et al. Cancer Res. 2010.
Abstract
Edmonston vaccine strains of measles virus (MV) have shown significant antitumor activity in preclinical models of ovarian cancer. We engineered MV to express the marker peptide carcinoembryonic antigen (MV-CEA virus) to also permit real-time monitoring of viral gene expression in tumors in the clinical setting. Patients with Taxol and platinum-refractory recurrent ovarian cancer and normal CEA levels were eligible for this phase I trial. Twenty-one patients were treated with MV-CEA i.p. every 4 weeks for up to 6 cycles at seven different dose levels (10(3)-10(9) TCID(50)). We observed no dose-limiting toxicity, treatment-induced immunosuppression, development of anti-CEA antibodies, increase in anti-MV antibody titers, or virus shedding in urine or saliva. Dose-dependent CEA elevation in peritoneal fluid and serum was observed. Immunohistochemical analysis of patient tumor specimens revealed overexpression of measles receptor CD46 in 13 of 15 patients. Best objective response was dose-dependent disease stabilization in 14 of 21 patients with a median duration of 92.5 days (range, 54-277 days). Five patients had significant decreases in CA-125 levels. Median survival of patients on study was 12.15 months (range, 1.3-38.4 months), comparing favorably to an expected median survival of 6 months in this patient population. Our findings indicate that i.p. administration of MV-CEA is well tolerated and results in dose-dependent biological activity in a cohort of heavily pretreated recurrent ovarian cancer patients.
Figures
Figure 1
Schematic representation of MV-CEA. The cDNA encoding for the human CEA was inserted upstream of the nucleoprotein (N) gene. P, phosphoprotein gene; M, matrix protein gene; F, fusion protein gene; L, large protein gene (adapted with permission from Peng KW et al., Nat Med 2002;8:527–31).
Figure 2
Treatment-related adverse events in cycle 1. MV-CEA treatment was well tolerated with only mild (grade 1 and 2) toxicity being observed.
Figure 3
A, mean serum anti-MV antibody titers at baseline and prior to the patients going off-study, presented per dose level. No significant difference was observed between pre- and post-treatment values. B, strong expression of MV receptor CD46 in the tumors of two study patients (A and B). C, serum CEA kinetics in a patient treated at the 109 TCID50 dose level. CEA elevation was observed even following repeat dosing although at gradually decreasing levels.
Figure 4
CA-125 response curves in two study patients who received six (patient A) and three (patient B) treatment cycles. Continued CA-125 response was observed in response to repeat viral dosing. Patient A maintained disease stability for 8 mo (i.e., 2 mo following treatment completion), whereas patient B had extra-abdominal (central nervous system) disease progression, while on treatment.
Similar articles
- Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter.
Hasegawa K, Pham L, O'Connor MK, Federspiel MJ, Russell SJ, Peng KW. Hasegawa K, et al. Clin Cancer Res. 2006 Mar 15;12(6):1868-75. doi: 10.1158/1078-0432.CCR-05-1803. Clin Cancer Res. 2006. PMID: 16551872 - Toxicology study of repeat intracerebral administration of a measles virus derivative producing carcinoembryonic antigen in rhesus macaques in support of a phase I/II clinical trial for patients with recurrent gliomas.
Myers R, Harvey M, Kaufmann TJ, Greiner SM, Krempski JW, Raffel C, Shelton SE, Soeffker D, Zollman P, Federspiel MJ, Blanco M, Galanis E. Myers R, et al. Hum Gene Ther. 2008 Jul;19(7):690-8. doi: 10.1089/hum.2008.035. Hum Gene Ther. 2008. PMID: 18576918 Free PMC article. - Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer.
Galanis E, Atherton PJ, Maurer MJ, Knutson KL, Dowdy SC, Cliby WA, Haluska P Jr, Long HJ, Oberg A, Aderca I, Block MS, Bakkum-Gamez J, Federspiel MJ, Russell SJ, Kalli KR, Keeney G, Peng KW, Hartmann LC. Galanis E, et al. Cancer Res. 2015 Jan 1;75(1):22-30. doi: 10.1158/0008-5472.CAN-14-2533. Epub 2014 Nov 14. Cancer Res. 2015. PMID: 25398436 Free PMC article. - Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview.
Msaouel P, Dispenzieri A, Galanis E. Msaouel P, et al. Curr Opin Mol Ther. 2009 Feb;11(1):43-53. Curr Opin Mol Ther. 2009. PMID: 19169959 Free PMC article. Review. - Measles to the Rescue: A Review of Oncolytic Measles Virus.
Aref S, Bailey K, Fielding A. Aref S, et al. Viruses. 2016 Oct 22;8(10):294. doi: 10.3390/v8100294. Viruses. 2016. PMID: 27782084 Free PMC article. Review.
Cited by
- Exploring treatment options in cancer: Tumor treatment strategies.
Liu B, Zhou H, Tan L, Siu KTH, Guan XY. Liu B, et al. Signal Transduct Target Ther. 2024 Jul 17;9(1):175. doi: 10.1038/s41392-024-01856-7. Signal Transduct Target Ther. 2024. PMID: 39013849 Free PMC article. Review. - Vaccine targeting to mucosal lymphoid tissues promotes humoral immunity in the gastrointestinal tract.
Kocabiyik O, Amlashi P, Vo AL, Suh H, Rodriguez-Aponte SA, Dalvie NC, Love JC, Andrabi R, Irvine DJ. Kocabiyik O, et al. Sci Adv. 2024 May 31;10(22):eadn7786. doi: 10.1126/sciadv.adn7786. Epub 2024 May 29. Sci Adv. 2024. PMID: 38809992 Free PMC article. - Dual‑regulated oncolytic adenovirus carrying _ERCC1_‑siRNA gene possesses potent antitumor effect on ovarian cancer cells.
Zhao T, Ye W, Zhang R, Zhu X, Shi Q, Xu X, Chen W, Xu L, Meng Y. Zhao T, et al. Mol Med Rep. 2024 Jul;30(1):120. doi: 10.3892/mmr.2024.13245. Epub 2024 May 17. Mol Med Rep. 2024. PMID: 38757346 Free PMC article. - Functional remodeling of intraperitoneal macrophages by oncolytic adenovirus restores anti-tumor immunity for peritoneal metastasis of gastric cancer.
Tabuchi M, Kikuchi S, Tazawa H, Okura T, Ogawa T, Mitsui E, Une Y, Kuroda S, Sato H, Noma K, Kagawa S, Ohara T, Ohtsuka J, Ohki R, Urata Y, Fujiwara T. Tabuchi M, et al. Mol Ther Oncol. 2024 Apr 24;32(2):200806. doi: 10.1016/j.omton.2024.200806. eCollection 2024 Jun 20. Mol Ther Oncol. 2024. PMID: 38745748 Free PMC article. - Mediation of antitumor activity by AZD4820 oncolytic vaccinia virus encoding IL-12.
Kurokawa C, Agrawal S, Mitra A, Galvani E, Burke S, Varshine A, Rothstein R, Schifferli K, Monks NR, Foloppe J, Silvestre N, Quemeneur E, Demeusoit C, Kleinpeter P, Sapra P, Barrett C, Hammond SA, Kelly EJ, Laliberte J, Durham NM, Oberst M, Broggi MAS. Kurokawa C, et al. Mol Ther Oncol. 2024 Jan 10;32(1):200758. doi: 10.1016/j.omton.2023.200758. eCollection 2024 Mar 21. Mol Ther Oncol. 2024. PMID: 38596304 Free PMC article.
References
- Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96. - PubMed
- McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334:1–6. - PubMed
- Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34–43. - PubMed
- Gordon EM, Chen ZH, Liu L, et al. Systemic administration of a matrix-targeted retroviral vector is efficacious for cancer gene therapy in mice. Hum Gene Ther. 2001;12:193–204. - PubMed
- Thigpen JT, Blessing JA, Ball H, Hummel SJ, Barrett RJ. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J Clin Oncol. 1994;12:1748–53. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 CA136547/CA/NCI NIH HHS/United States
- CA 103276/CA/NCI NIH HHS/United States
- U54RR 24150/RR/NCRR NIH HHS/United States
- P30 CA015083-32S1/CA/NCI NIH HHS/United States
- UL1 RR024150-03/RR/NCRR NIH HHS/United States
- P30 CA015083/CA/NCI NIH HHS/United States
- P50 CA136393-01A1/CA/NCI NIH HHS/United States
- N01 CA015083/CA/NCI NIH HHS/United States
- R21 CA103276-02/CA/NCI NIH HHS/United States
- R01 CA136547-02/CA/NCI NIH HHS/United States
- CA 136547/CA/NCI NIH HHS/United States
- R21 CA103276-01/CA/NCI NIH HHS/United States
- CA 136393/CA/NCI NIH HHS/United States
- UL1 RR024150/RR/NCRR NIH HHS/United States
- CA 15083/CA/NCI NIH HHS/United States
- P50 CA136393/CA/NCI NIH HHS/United States
- P50 CA136393-01A17925/CA/NCI NIH HHS/United States
- R21 CA103276/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous